UCLA Jonsson Comprehensive Cancer Center researchers presented research at the San Antonio Breast Cancer Symposium showing that a subgroup analysis of a phase III study found consistent ...

Larynx-preserving treatment strategy for patients with resectable cervical esophageal squamous cell carcinoma. This is an ASCO Meeting Abstract from the 2024 ASCO Gastrointestinal Cancers Symposium.

Trastuzumab deruxtecan-THP was associated with a statistically significant and clinically meaningful improvement in pathologic complete response rate vs standard of care. The DESTINY-Breast11 trial ...

One year of adjuvant trastuzumab is standard for early stage (I-III) HER2+ breast cancer (BC) patients. Cardiac imaging is recommended every 3 months during treatment to monitor for cardiotoxicity ...

Using Medicare claims, we documented US prescribing patterns for originator biologic trastuzumab (Herceptin), a targeted cancer therapy, and five biosimilar entrants since 2019. The first biosimilar ...

AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been approved by the US Food and Drug Administration (FDA) for both the neoadjuvant and adjuvant treatment of patients ...

The approval came exactly 2 months after results from the landmark DESTINY-Breast04 trial showed that the antibody drug conjugate reduced the risk of disease progression or death by 50% compared with ...

A combination of HER2-targeted drugs used in breast cancer is now available for use in colorectal cancer. This is the first FDA-approved treatment for HER2-positive metastatic colorectal cancer, maker ...

Between September 2007 and January 2009, patients with HER2-positive breast cancer were recruited before therapy with trastuzumab. Individuals with negative HER2 and healthy controls were also ...

Impact of peridiagnostic genetic counseling and germline testing on treatment decisions for patients with triple negative breast cancer undergoing pembrolizumab-chemotherapy neoadjuvant approach. This ...

Please provide your email address to receive an email when new articles are posted on . CHICAGO — Trastuzumab deruxtecan extended PFS compared with standard chemotherapy for certain patients with ...